Mortality associated with breakthrough candidemia among patients with and those without cancer
Krcmery, V.C.; Babela, R.
Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 35(7): 898; author reply 899
2002
ISSN/ISBN: 1058-4838
PMID: 12228832
DOI: 10.1086/341987
Accession: 003854656
This study was a retrospective review of all cases of breakthrough candidaemia (BC; mostly caused by Candida albicans and C. parapsilosis) that occurred during a national survey (1990-99) of the incidence of candidaemia in Slovakia: 62 cases occurred in patients with neoplasm and 47 in patients without neoplasm. Among the 62 patients with neoplasm and BC, overall mortality was ~33% and attributable mortality was ~22.5%; those without BC (control subjects), overall mortality was ~36% and attributable mortality was ~21%. Among patients with BC but without neoplasm, overall mortality was ~25.3%, and attributable mortality was ~18.2%.
PDF emailed within 0-6 h: $19.90
Related References
Kontoyiannis, D.P.; Reddy, B.T.; Hanna, H.; Bodey, G.P.; Tarrand, J.; Raad, I.I. 2002: Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity Infection Control and Hospital Epidemiology 23(9): 542-545Barrientos, A.C.M.; Nobrega de Almeida Junior, J.ão.; Litvinov, N.; Bain, V.; Cristofani, L.M.; Badue Pereira, M.F.; Sanson Yoshino de Paula, C.; Lopes Motta, A.; Rossi, F.; Bárbaro Del Negro, G.M.; Yamamoto Thomaz, D.; Sousa Marques, H.H. 2021: Breakthrough Candidemia in Pediatric Patients with Cancer from a Brazilian Center Pediatric Infectious Disease Journal 40(3): 251-254
Uzun, O.; Ascioglu, S.; Anaissie, E.J.; Rex, J.H. 2001: Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 32(12): 1713-1717
Morgan, J.; Meltzer, M.I.; Plikaytis, B.D.; Sofair, A.N.; Huie-White, S.; Wilcox, S.; Harrison, L.H.; Seaberg, E.C.; Hajjeh, R.A.; Teutsch, S.M. 2005: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance Infection Control and Hospital Epidemiology 26(6): 540-547
Nucci, M.; Colombo, A.L. 2002: Risk factors for breakthrough candidemia European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 21(3): 209-211
Nucci, M.; Colombo, A.L.; Spector, N.; Velasco, E.; Martins, C.A.; Pulcheri, W. 1997: Breakthrough candidemia in neutropenic patients Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 24(2): 275-276
Funaki, T.; Miyairi, I. 2018: Breakthrough Candidemia in Children on Micafungin Pediatric Infectious Disease Journal 37(12): 1258-1260
Uraguchi, K.; Makino, T.; Kariya, S.; Noda, Y.; Marunaka, H.; Doi, A.; Kozakura, K.; Takao, S.; Ando, M. 2022: Candidemia in patients with head and neck cancer: mortality and a novel risk factor Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 30(7): 5921-5930
Taur, Y.; Cohen, N.; Dubnow, S.; Paskovaty, A.; Seo, S.K. 2010: Effect of antifungal therapy timing on mortality in cancer patients with candidemia Antimicrobial Agents and ChemoTherapy 54(1): 184-190
Abe, M.; Kimura, M.; Araoka, H.; Taniguchi, S.; Yoneyama, A. 2014: Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia Medical Mycology 52(8): 835-840
Girmenia, C.; Martino, P.; Cassone, A. 1996: Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies Blood 87(2): 838-839
Bizerra, F.C.és.; Jimenez-Ortigosa, C.; Souza, A.C.R.; Breda, G.L.; Queiroz-Telles, F.áv.; Perlin, D.S.; Colombo, A.L. 2014: Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin Antimicrobial Agents and ChemoTherapy 58(4): 2438-2440
Lai, M.-Y.; Hsu, J.-F.; Chu, S.-M.; Wu, I.-H.; Huang, H.-R.; Lin, C.-C.; Lee, I.-T.; Chiang, M.-C.; Fu, R.-H.; Tsai, M.-H. 2017: Breakthrough candidemia in children: clinical and microbiological characteristics, therapeutic strategies and impact on outcomes Future Microbiology 12: 695-705
Orasch, C.; Mertz, D.; Garbino, J.; van Delden, C.; Emonet, S.; Schrenzel, J.; Zimmerli, S.; Damonti, L.; Mühlethaler, K.; Imhof, A.; Ruef, C.; Fehr, J.; Zbinden, R.; Boggian, K.; Bruderer, T.; Flückiger, U.; Conen, A.; Khanna, N.; Frei, R.; Bregenzer, T.; Lamoth, F.éd.ér.; Erard, V.ér.; Bochud, P.-Y.; Calandra, T.; Bille, J.; Marchetti, O.; Bregenzer, T.; Conen, A.; Flückiger, U.; Khanna, N.; Orasch, C.; Heininger, U.; Franciolli, M.; Damonti, L.; Zimmerli, S.; Rothen, M.; Zellweger, C.; Rothen, M.; Tarr, P.; Fleisch, F.; Chuard, C.; Erard, V.ér.; Emonet, S.ép.; Garbino, J.; van Delden, C.; Genne, D.; Bochud, P.-Y.; Calandra, T.; Damonti, L.; Erard, V.ér.; Lamoth, F.éd.ér.; Marchetti, O.; Orasch, C.; Chave, J.-P.; Graber, P.; Mo 2018: Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study Journal of Infection 76(5): 489-495
Breda, G.L.; Tuon, F.F.; Meis, J.F.; Herkert, P.F.; Hagen, F.; de Oliveira, Lícia.Z.; Dias, V.de.Carvalho.; da Cunha, Cóvis.Arns.; Queiroz-Telles, Fávio. 2018: Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study Medical Mycology 56(4): 406-415
Kimura, M.; Araoka, H.; Yamamoto, H.; Asano-Mori, Y.; Nakamura, S.; Yamagoe, S.; Ohno, H.; Miyazaki, Y.; Abe, M.; Yuasa, M.; Kaji, D.; Kageyama, K.; Nishida, A.; Ishiwata, K.; Takagi, S.; Yamamoto, G.; Uchida, N.; Izutsu, K.; Wake, A.; Taniguchi, S.; Yoneyama, A. 2017: Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital Antimicrobial Agents and ChemoTherapy 61(4)
Al-Obaid, I.; Asadzadeh, M.; Ahmad, S.; Alobaid, K.; Alfouzan, W.; Bafna, R.; Emara, M.; Joseph, L. 2022: Fatal Breakthrough Candidemia in an Immunocompromised Patient in Kuwait Due to Candida auris Exhibiting Reduced Susceptibility to Echinocandins and Carrying a Novel Mutation in Hotspot-1 of FKS1 Journal of Fungi 8(3)
Kaito, S.; Sekiya, N.; Najima, Y.; Suzuki, T.; Wada, A.; Adachi, H.; Konuma, R.; Kishida, Y.; Nagata, A.; Konishi, T.; Yamada, Y.; Kumagai, T.; Inamoto, K.; Yoshifuji, K.; Akiyama, M.; Toya, T.; Igarashi, A.; Muto, H.; Doki, N.; Kobayashi, T.; Kakihana, K.; Ohashi, K. 2020: Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation Bone Marrow Transplantation 55(3): 661-664
Hirano, R.; Sakamoto, Y.; Kitazawa, J.; Yamamoto, S.; Kayaba, H. 2018: Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections: a single tertiary hospital experience in Japan Infection and Drug Resistance 11: 821-833
Goel, G.; Chandy, M.; Bhattacharyya, A.; Banerjee, S.; Chatterjee, S.; Mullick, S.; Sinha, S.; Sengupta, K.; Dhar, K.; Bhattacharya, S.; Rudramurthy, S.; Chakrabarti, A. 2017: Mortality associated with candidemia in non-neutropenic cancer patients is not less compared to a neutropenic cohort of cancer patients European Journal of Clinical Microbiology and Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 36(12): 2533-2535